What is BC Platforms?
Based in Zurich, Switzerland, BC Platforms specializes in genomics and clinical data solutions, offering advanced analytics for personalized medicine and research. The company's platform is designed to manage and analyze complex healthcare data, facilitating breakthroughs in medical research and patient care. The recent enterprise-level funding indicates a strong market position and confidence in BC Platforms' innovative approach to healthcare data.
How much funding has BC Platforms raised?
BC Platforms has raised a total of $48.4M across 5 funding rounds:
Debt
$1.7M
Series A
$1.7M
Series B
$10M
Series C
$15M
Other Financing Round
$20M
Debt (2016): $1.7M, investors not publicly disclosed
Series A (2016): $1.7M led by Boston Millennia Partners
Series B (2017): $10M supported by Tesi
Series C (2019): $15M featuring Debiopharm Innovation Fund, Tesi, and IQVIA
Other Financing Round (2022): $20M backed by Jolt Capital
Key Investors in BC Platforms
Jolt Capital
Jolt Capital is a private equity firm that specializes in growth-stage deeptech companies, focusing on sectors such as cybersecurity, semiconductors, and advanced materials. The firm provides growth capital ranging from 10M to 50M euros to enable these companies to scale and expand into new markets while mitigating risks.
Tesi
Tesi (Finnish Industry Investment Ltd) is a venture capital and private equity company that accelerates companies' success stories by investing in them directly and via funds. Tesi always invests together with other investors, providing them with access to high quality deal-flow in Finland.
IQVIA
IQVIA is a global provider of information, innovative technology solutions and contract research services focused on using data and science to help healthcare clients find solutions for their patients. IQVIA offers a broad range of solutions that harness advances in healthcare information, technology, analytics and human ingenuity to drive healthcare forward.
What's next for BC Platforms?
With this substantial strategic investment, BC Platforms is poised for accelerated growth and expansion. The company is expected to further enhance its data management and analytics capabilities, potentially broadening its reach into new therapeutic areas and geographical markets. This capital infusion will likely support advancements in their genomic and clinical data solutions, reinforcing their role in driving personalized medicine forward and solidifying their competitive edge in the health-tech landscape.
See full BC Platforms company page
